PASITHEA THERAPEUTICS CORP. Asset Acquisition Consideration Transferred Transaction Cost
PASITHEA THERAPEUTICS CORP. (KTTA) reported Asset Acquisition Consideration Transferred Transaction Cost of $697.12 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-29.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost · last filed 2024-03-29
- PASITHEA THERAPEUTICS CORP. asset acquisition consideration transferred transaction cost for fiscal 2023 was $697.12K, a 2.52% increase from fiscal 2022.
- PASITHEA THERAPEUTICS CORP. asset acquisition consideration transferred transaction cost for fiscal 2022 was $680.00K.
| Period end | Asset Acquisition Consideration Transferred Transaction Cost 12 month |
|---|---|
| 2023-12-31 | $697.12K 10-K · filed 2024-03-29 |
| 2022-12-31 | $680.00K 10-K · filed 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Rocket One Inc. (RKTO) | United States | $0.019B |